P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use

about

Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome.Acquired Hemophilia A May Be Associated with Ticagrelor Therapy in a 52-Year-Old Man After a Recent Percutaneous Transluminal Coronary Angioplasty.

P2860

Q38677500-1F309939-2BBE-4F6D-80AD-6FFB38522332 Q41089560-820D7288-8656-4BFD-B108-D440C332A797

P2860

P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use

Item

http://www.wikidata.org/entity/Q38542096

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

P2Y12 antagonists in non-ST-se ...... atest evidence and optimal use

@en

type

Item

label

P2Y12 antagonists in non-ST-se ...... atest evidence and optimal use

@en

prefLabel

P2Y12 antagonists in non-ST-se ...... atest evidence and optimal use

@en

P1476

P2Y12 antagonists in non-ST-se ...... atest evidence and optimal use

@en

P2093

Nicholas B Norgard

http://www.w3.org/2001/XMLSchema#string

P2860

Periprocedural Myocardial Infarction: Prevalence, Prognosis, and Prevention

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

Early and late effects of clopidogrel in patients with acute coronary syndromes

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necro

P304

204-218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2040622315584113

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

James J DiNicolantonio

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

277913497

http://www.w3.org/2001/XMLSchema#string

P698

26137210

http://www.w3.org/2001/XMLSchema#string

P932

4480548

http://www.w3.org/2001/XMLSchema#string

P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use

about

P2860

P2860

P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P932